Jazz Pharmaceuticals plc
http://jazzpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jazz Pharmaceuticals plc
FDA’s Orange Book Dispute Resolution Process May Grow Teeth With FTC Patent Listing Challenges
People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.
FTC Campaign Against Orange Book Patent Listings Extends To Mylan’s Battle With Sanofi
Sanofi’s Orange Book listings for its insulin glargine product ‘can be viewed as one part of an overarching monopolistic scheme,’ FTC says in amicus brief.
FTC Campaign Against Orange Book Patent Listings Extends To Mylan’s Battle With Sanofi
Sanofi’s Orange Book listings for its insulin glargine product ‘can be viewed as one part of an overarching monopolistic scheme,’ FTC says in amicus brief.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Company Information
- Industry
- Biotechnology
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice